Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study

Baseline ctDNA above the median MMPM was associated with shorter PFS and OS in both arms (Pola-R-CHP PFS HR 1.96, OS HR 2.17; R-CHOP PFS HR 1.43, OS HR 2.10). A log-fold change of at least 2.0 or undetectable ctDNA at C2D1 was reached by 66.8% and 65.6% of patients in the two arms and was prognostic (PFS HR 1.86 and 2.21). In Pola-R-CHP, a 2.5-log reduction (PFS HR 2.89) and C2D1 clearance (PFS HR 2.98, OS HR 2.74) remained prognostic independent of baseline risk factors.

ASH Annual Meeting 2022